U.S. markets closed
  • S&P Futures

    4,122.00
    -2.50 (-0.06%)
     
  • Dow Futures

    32,723.00
    -14.00 (-0.04%)
     
  • Nasdaq Futures

    13,022.75
    -8.75 (-0.07%)
     
  • Russell 2000 Futures

    1,912.80
    -1.80 (-0.09%)
     
  • Crude Oil

    90.33
    -0.17 (-0.19%)
     
  • Gold

    1,792.40
    -1.60 (-0.09%)
     
  • Silver

    20.47
    -0.01 (-0.06%)
     
  • EUR/USD

    1.0207
    -0.0010 (-0.10%)
     
  • 10-Yr Bond

    2.7970
    +0.0320 (+1.16%)
     
  • Vix

    21.77
    +0.48 (+2.25%)
     
  • GBP/USD

    1.2071
    -0.0005 (-0.04%)
     
  • USD/JPY

    135.2500
    +0.1340 (+0.10%)
     
  • BTC-USD

    23,062.62
    -766.72 (-3.22%)
     
  • CMC Crypto 200

    536.00
    -21.35 (-3.83%)
     
  • FTSE 100

    7,488.15
    +5.78 (+0.08%)
     
  • Nikkei 225

    27,738.34
    -261.62 (-0.93%)
     

Here's Why You Should Retain Fresenius Medical (FMS) Stock Now

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Fresenius Medical Care AG & Co. KGaA FMS is well-poised for growth on the back of a broad range of dialysis products and services and a solid global foothold. However, stiff competition remains a concern.

Shares of this Zacks Rank #3 (Hold) company have lost 18.1% compared with the industry’s decline of 30.8% in a year’s time. The S&P 500 Index has plunged 18.6% in the same time frame.

The company — with a market capitalization of $15.79 billion — is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. It anticipates earnings to improve 12.5% over the next five years. It beat earnings estimates in three of the trailing four quarters and missed once, the average surprise being 5.2%.

Key Catalysts

Fresenius Medical provides a wide range of Dialysis products in its own dialysis clinics and third-party clinics. These include modular machine components, dialyzers, bloodline systems, HD (hemodialysis) solutions, concentrates and water treatment systems.

Fresenius Medical offers a wide array of Hemodyalisis, Peritoneal dialysis and Acute Dialysis products. Per the fourth-quarter 2021 earnings release, in order to further boost the quality of life for its patients and increase their choice of available treatment options, Fresenius Medical Care is focused on further expanding its home dialysis offerings.

In April 2022, the company received 510(k) clearance from the FDA for Versi PD Cycler System – the next-generation portable automated peritoneal dialysis system from Fresenius Medical Care North America. It is noteworthy that this dialysis system is a simple, quiet, portable and advanced and has been developed to boost health equity for making home therapy more viable for a wider pool of dialysis patients.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Fresenius Medical has a solid market hold in the regions of North America, Europe (EMEA), the Asia Pacific and Latin America. To strengthen its market position, the company is resorting to various approaches like enhancing its organic growth and making strategic and suitable acquisitions. The company also aims to align its business activities through public-private partnerships in the dialysis business to tap into new markets in the coming quarters.

In the first quarter of 2022, the company witnessed strong contributions of 4%, 2% and 16% from the Asia Pacific, EMEA and Latin America, respectively.

What’s Hurting the Stock?

Fresenius Medical has numerous competitors in the field of health care services and the sale of dialysis products. Intense competition in the niche markets is likely to hamper the company’s sales opportunities, which in turn can lead to a loss of market share.

Estimate Trend

The Zacks Consensus Estimate for 2023 revenues is pegged at $21.12 billion, suggesting growth of 4.2% from the year-ago reported number, while the same for earnings stands at $2.26 per share, indicating a rise of 13.4%.

Stocks to Consider

Some better-ranked stocks in the broader medical space are AMN Healthcare Services, Inc. AMN, Masimo Corporation MASI and ShockWave Medical, Inc. SWAV.

AMN Healthcare surpassed earnings estimates in each of the trailing four quarters, the average surprise being 15.6%. The company currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

AMN Healthcare’s long-term earnings growth rate is estimated at 1.1%. The company’s earnings yield of 11.4% compares favorably with the industry’s (0.8%).

Masimo beat earnings estimates in each of the trailing four quarters, the average surprise being 4.4%. The company currently carries a Zacks Rank #2 (Buy).

Masimo’s estimated earnings growth rate for second-quarter 2022 is pegged at 22.3%. The company’s earnings yield is 3.8% against the industry’s (8.5%).

ShockWave Medical surpassed earnings estimates in all of the trailing four quarters, the average surprise being 189.9%. The company currently sports a Zacks Rank #1.

ShockWave Medical’s earnings growth rate for 2022 is estimated at 807.7%. The company’s earnings yield of 0.9% compares favorably with the industry’s (8%).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research